nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Arylamine metabolism—NAT2—liver cancer	0.00522	0.059	CbGpPWpGaD
Anagrelide—Abnormal vision—Epirubicin—liver cancer	0.00297	0.00326	CcSEcCtD
Anagrelide—Dyspnoea—Sorafenib—liver cancer	0.00293	0.00322	CcSEcCtD
Anagrelide—Lymphadenopathy—Epirubicin—liver cancer	0.0029	0.00318	CcSEcCtD
Anagrelide—Cramps of lower extremities—Doxorubicin—liver cancer	0.0029	0.00318	CcSEcCtD
Anagrelide—Dyspepsia—Sorafenib—liver cancer	0.0029	0.00318	CcSEcCtD
Anagrelide—Decreased appetite—Sorafenib—liver cancer	0.00286	0.00314	CcSEcCtD
Anagrelide—Ecchymosis—Doxorubicin—liver cancer	0.00285	0.00313	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Sorafenib—liver cancer	0.00284	0.00312	CcSEcCtD
Anagrelide—Fatigue—Sorafenib—liver cancer	0.00284	0.00311	CcSEcCtD
Anagrelide—Photosensitivity—Epirubicin—liver cancer	0.00282	0.00309	CcSEcCtD
Anagrelide—Pain—Sorafenib—liver cancer	0.00281	0.00309	CcSEcCtD
Anagrelide—Constipation—Sorafenib—liver cancer	0.00281	0.00309	CcSEcCtD
Anagrelide—Abnormal vision—Doxorubicin—liver cancer	0.00275	0.00302	CcSEcCtD
Anagrelide—Cardiac failure congestive—Epirubicin—liver cancer	0.00273	0.00299	CcSEcCtD
Anagrelide—Gastrointestinal pain—Sorafenib—liver cancer	0.00269	0.00295	CcSEcCtD
Anagrelide—Lymphadenopathy—Doxorubicin—liver cancer	0.00268	0.00294	CcSEcCtD
Anagrelide—Urticaria—Sorafenib—liver cancer	0.00261	0.00287	CcSEcCtD
Anagrelide—Photosensitivity—Doxorubicin—liver cancer	0.00261	0.00286	CcSEcCtD
Anagrelide—Abdominal pain—Sorafenib—liver cancer	0.0026	0.00285	CcSEcCtD
Anagrelide—Body temperature increased—Sorafenib—liver cancer	0.0026	0.00285	CcSEcCtD
Anagrelide—Renal impairment—Epirubicin—liver cancer	0.0026	0.00285	CcSEcCtD
Anagrelide—Cardiac failure—Epirubicin—liver cancer	0.00254	0.00278	CcSEcCtD
Anagrelide—Cerebrovascular accident—Epirubicin—liver cancer	0.00253	0.00277	CcSEcCtD
Anagrelide—Cardiac failure congestive—Doxorubicin—liver cancer	0.00252	0.00277	CcSEcCtD
Anagrelide—Osteoarthritis—Epirubicin—liver cancer	0.00247	0.00271	CcSEcCtD
Anagrelide—Diplopia—Epirubicin—liver cancer	0.00247	0.00271	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00247	0.00271	CcSEcCtD
Anagrelide—Migraine—Epirubicin—liver cancer	0.00244	0.00267	CcSEcCtD
Anagrelide—Renal impairment—Doxorubicin—liver cancer	0.00241	0.00264	CcSEcCtD
Anagrelide—Asthenia—Sorafenib—liver cancer	0.00236	0.00259	CcSEcCtD
Anagrelide—Cardiac failure—Doxorubicin—liver cancer	0.00235	0.00257	CcSEcCtD
Anagrelide—Cerebrovascular accident—Doxorubicin—liver cancer	0.00234	0.00256	CcSEcCtD
Anagrelide—Pruritus—Sorafenib—liver cancer	0.00233	0.00255	CcSEcCtD
Anagrelide—Blood creatinine increased—Epirubicin—liver cancer	0.00232	0.00254	CcSEcCtD
Anagrelide—Dehydration—Epirubicin—liver cancer	0.0023	0.00252	CcSEcCtD
Anagrelide—Diplopia—Doxorubicin—liver cancer	0.00229	0.00251	CcSEcCtD
Anagrelide—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00229	0.00251	CcSEcCtD
Anagrelide—Osteoarthritis—Doxorubicin—liver cancer	0.00229	0.00251	CcSEcCtD
Anagrelide—Liver function test abnormal—Epirubicin—liver cancer	0.00228	0.00251	CcSEcCtD
Anagrelide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00228	0.0258	CbGpPWpGaD
Anagrelide—Dry skin—Epirubicin—liver cancer	0.00227	0.00249	CcSEcCtD
Anagrelide—Orthostatic hypotension—Epirubicin—liver cancer	0.00226	0.00248	CcSEcCtD
Anagrelide—Migraine—Doxorubicin—liver cancer	0.00225	0.00247	CcSEcCtD
Anagrelide—Diarrhoea—Sorafenib—liver cancer	0.00225	0.00247	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—GSTA1—liver cancer	0.00219	0.0248	CbGpPWpGaD
Anagrelide—Gastritis—Epirubicin—liver cancer	0.00219	0.0024	CcSEcCtD
Anagrelide—Dizziness—Sorafenib—liver cancer	0.00218	0.00239	CcSEcCtD
Anagrelide—Blood creatinine increased—Doxorubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Anagrelide—Influenza—Epirubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Anagrelide—Asthma—Epirubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Anagrelide—Dysphagia—Epirubicin—liver cancer	0.00214	0.00235	CcSEcCtD
Anagrelide—Dehydration—Doxorubicin—liver cancer	0.00213	0.00234	CcSEcCtD
Anagrelide—Liver function test abnormal—Doxorubicin—liver cancer	0.00211	0.00232	CcSEcCtD
Anagrelide—Dry skin—Doxorubicin—liver cancer	0.0021	0.0023	CcSEcCtD
Anagrelide—Pancreatitis—Epirubicin—liver cancer	0.0021	0.0023	CcSEcCtD
Anagrelide—Vomiting—Sorafenib—liver cancer	0.00209	0.0023	CcSEcCtD
Anagrelide—Orthostatic hypotension—Doxorubicin—liver cancer	0.00209	0.00229	CcSEcCtD
Anagrelide—Angina pectoris—Epirubicin—liver cancer	0.00208	0.00229	CcSEcCtD
Anagrelide—Rash—Sorafenib—liver cancer	0.00207	0.00228	CcSEcCtD
Anagrelide—Dermatitis—Sorafenib—liver cancer	0.00207	0.00227	CcSEcCtD
Anagrelide—Headache—Sorafenib—liver cancer	0.00206	0.00226	CcSEcCtD
Anagrelide—Bronchitis—Epirubicin—liver cancer	0.00206	0.00226	CcSEcCtD
Anagrelide—Pancytopenia—Epirubicin—liver cancer	0.00203	0.00223	CcSEcCtD
Anagrelide—Gastritis—Doxorubicin—liver cancer	0.00203	0.00222	CcSEcCtD
Anagrelide—Dysuria—Epirubicin—liver cancer	0.002	0.00219	CcSEcCtD
Anagrelide—Asthma—Doxorubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Anagrelide—Influenza—Doxorubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Anagrelide—Dysphagia—Doxorubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Anagrelide—Pollakiuria—Epirubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Anagrelide—Nausea—Sorafenib—liver cancer	0.00195	0.00214	CcSEcCtD
Anagrelide—Photosensitivity reaction—Epirubicin—liver cancer	0.00195	0.00214	CcSEcCtD
Anagrelide—Weight increased—Epirubicin—liver cancer	0.00195	0.00214	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—liver cancer	0.00194	0.0219	CbGpPWpGaD
Anagrelide—Pancreatitis—Doxorubicin—liver cancer	0.00194	0.00213	CcSEcCtD
Anagrelide—Weight decreased—Epirubicin—liver cancer	0.00193	0.00212	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—liver cancer	0.00193	0.00211	CcSEcCtD
Anagrelide—Pneumonia—Epirubicin—liver cancer	0.00192	0.0021	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—liver cancer	0.0019	0.00209	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—liver cancer	0.00188	0.00206	CcSEcCtD
Anagrelide—Renal failure—Epirubicin—liver cancer	0.00187	0.00206	CcSEcCtD
Anagrelide—Conjunctivitis—Epirubicin—liver cancer	0.00185	0.00203	CcSEcCtD
Anagrelide—Urinary tract infection—Epirubicin—liver cancer	0.00185	0.00203	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—liver cancer	0.00185	0.00203	CcSEcCtD
Anagrelide—Sweating—Epirubicin—liver cancer	0.00183	0.00201	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—liver cancer	0.00183	0.00201	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—liver cancer	0.00182	0.00199	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—liver cancer	0.00181	0.00198	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—liver cancer	0.0018	0.00198	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—liver cancer	0.0018	0.00198	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—liver cancer	0.0018	0.00197	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—liver cancer	0.00179	0.00196	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—liver cancer	0.00179	0.00196	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—liver cancer	0.00177	0.00195	CcSEcCtD
Anagrelide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.00177	0.02	CbGpPWpGaD
Anagrelide—Renal failure—Doxorubicin—liver cancer	0.00173	0.0019	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—liver cancer	0.00172	0.00189	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—liver cancer	0.00171	0.00188	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—liver cancer	0.00171	0.00188	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—liver cancer	0.0017	0.00187	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—liver cancer	0.0017	0.00186	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—liver cancer	0.00169	0.00186	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—liver cancer	0.00169	0.00185	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—liver cancer	0.00169	0.00185	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—liver cancer	0.00168	0.00185	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—liver cancer	0.00168	0.00185	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—liver cancer	0.00168	0.00184	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—liver cancer	0.00167	0.00183	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—liver cancer	0.00166	0.00183	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—liver cancer	0.00166	0.00182	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—liver cancer	0.00165	0.00181	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—liver cancer	0.0016	0.00175	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—liver cancer	0.0016	0.00175	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—liver cancer	0.00159	0.00175	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—liver cancer	0.00158	0.00174	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—liver cancer	0.00158	0.00174	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—liver cancer	0.00158	0.00173	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—liver cancer	0.00157	0.00172	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—liver cancer	0.00156	0.00172	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—liver cancer	0.00156	0.00171	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00156	0.0176	CbGpPWpGaD
Anagrelide—Connective tissue disorder—Doxorubicin—liver cancer	0.00156	0.00171	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—liver cancer	0.00155	0.0017	CcSEcCtD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00155	0.0175	CbGpPWpGaD
Anagrelide—Mediastinal disorder—Epirubicin—liver cancer	0.00154	0.00169	CcSEcCtD
Anagrelide—Chills—Epirubicin—liver cancer	0.00154	0.00168	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00153	0.0173	CbGpPWpGaD
Anagrelide—Arrhythmia—Epirubicin—liver cancer	0.00153	0.00168	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—liver cancer	0.00153	0.00167	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—liver cancer	0.00151	0.00166	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—HBE1—liver cancer	0.00149	0.0169	CbGpPWpGaD
Anagrelide—Malnutrition—Epirubicin—liver cancer	0.00149	0.00163	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—liver cancer	0.00148	0.00162	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—liver cancer	0.00148	0.00162	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—liver cancer	0.00147	0.00161	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—liver cancer	0.00147	0.00161	CcSEcCtD
Anagrelide—Tension—Epirubicin—liver cancer	0.00146	0.0016	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—liver cancer	0.00145	0.00159	CcSEcCtD
Anagrelide—Back pain—Epirubicin—liver cancer	0.00144	0.00158	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—liver cancer	0.00143	0.00157	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—liver cancer	0.00143	0.00157	CcSEcCtD
Anagrelide—Chills—Doxorubicin—liver cancer	0.00142	0.00156	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—liver cancer	0.00141	0.00155	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—liver cancer	0.0014	0.00154	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—liver cancer	0.0014	0.00154	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—liver cancer	0.00138	0.00152	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—liver cancer	0.00138	0.00151	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—liver cancer	0.00138	0.00151	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—liver cancer	0.00136	0.00149	CcSEcCtD
Anagrelide—Tension—Doxorubicin—liver cancer	0.00135	0.00148	CcSEcCtD
Anagrelide—Malaise—Epirubicin—liver cancer	0.00134	0.00147	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—liver cancer	0.00134	0.00147	CcSEcCtD
Anagrelide—Syncope—Epirubicin—liver cancer	0.00134	0.00147	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—liver cancer	0.00133	0.00146	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—liver cancer	0.00133	0.00145	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—liver cancer	0.00132	0.00144	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—liver cancer	0.00132	0.0149	CbGpPWpGaD
Anagrelide—Loss of consciousness—Epirubicin—liver cancer	0.00131	0.00144	CcSEcCtD
Anagrelide—Cough—Epirubicin—liver cancer	0.0013	0.00143	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—liver cancer	0.0013	0.00143	CcSEcCtD
Anagrelide—CYP1A2—Xenobiotics—CYP2E1—liver cancer	0.0013	0.0147	CbGpPWpGaD
Anagrelide—Convulsion—Epirubicin—liver cancer	0.00129	0.00142	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—liver cancer	0.00129	0.00141	CcSEcCtD
Anagrelide—PDE3A—Platelet homeostasis—MAPK14—liver cancer	0.00129	0.0145	CbGpPWpGaD
Anagrelide—Ill-defined disorder—Doxorubicin—liver cancer	0.00128	0.0014	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—liver cancer	0.00127	0.0014	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—liver cancer	0.00127	0.00139	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—liver cancer	0.00127	0.00139	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—liver cancer	0.00127	0.00139	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00126	0.00138	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—liver cancer	0.00125	0.00138	CcSEcCtD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP2E1—liver cancer	0.00125	0.0141	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—UGDH—liver cancer	0.00125	0.0141	CbGpPWpGaD
Anagrelide—Malaise—Doxorubicin—liver cancer	0.00124	0.00136	CcSEcCtD
Anagrelide—CYP1A2—Aflatoxin activation and detoxification—GGT1—liver cancer	0.00124	0.014	CbGpPWpGaD
Anagrelide—Dry mouth—Epirubicin—liver cancer	0.00124	0.00136	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—liver cancer	0.00124	0.00136	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—liver cancer	0.00123	0.00135	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—liver cancer	0.00122	0.00134	CcSEcCtD
Anagrelide—Oedema—Epirubicin—liver cancer	0.00122	0.00133	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—liver cancer	0.00121	0.00133	CcSEcCtD
Anagrelide—Infection—Epirubicin—liver cancer	0.00121	0.00133	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—PPARA—liver cancer	0.0012	0.0136	CbGpPWpGaD
Anagrelide—Cough—Doxorubicin—liver cancer	0.0012	0.00132	CcSEcCtD
Anagrelide—Shock—Epirubicin—liver cancer	0.0012	0.00131	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—liver cancer	0.00119	0.00131	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—liver cancer	0.00119	0.00131	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—liver cancer	0.00119	0.00131	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—liver cancer	0.00119	0.00131	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—liver cancer	0.00119	0.0013	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—liver cancer	0.00118	0.0013	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—liver cancer	0.00118	0.00129	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—liver cancer	0.00117	0.00129	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—liver cancer	0.00117	0.00129	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—liver cancer	0.00117	0.00129	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00117	0.00128	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—liver cancer	0.00116	0.00127	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—liver cancer	0.00116	0.00127	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—liver cancer	0.00115	0.00126	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—liver cancer	0.00114	0.00125	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—liver cancer	0.00113	0.00124	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—liver cancer	0.00113	0.00123	CcSEcCtD
Anagrelide—Infection—Doxorubicin—liver cancer	0.00112	0.00123	CcSEcCtD
Anagrelide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.00111	0.0126	CbGpPWpGaD
Anagrelide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00111	0.00122	CcSEcCtD
Anagrelide—Shock—Doxorubicin—liver cancer	0.00111	0.00121	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—liver cancer	0.0011	0.00121	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—liver cancer	0.0011	0.00121	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—liver cancer	0.0011	0.0124	CbGpPWpGaD
Anagrelide—Insomnia—Epirubicin—liver cancer	0.0011	0.00121	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—liver cancer	0.00109	0.0012	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—liver cancer	0.00109	0.0012	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—ESR1—liver cancer	0.00109	0.0123	CbGpPWpGaD
Anagrelide—Hyperhidrosis—Doxorubicin—liver cancer	0.00109	0.00119	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—liver cancer	0.00108	0.00119	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—liver cancer	0.00108	0.00119	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—liver cancer	0.00107	0.00118	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—GSTA2—liver cancer	0.00107	0.0121	CbGpPWpGaD
Anagrelide—Dyspepsia—Epirubicin—liver cancer	0.00107	0.00117	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—GSTM1—liver cancer	0.00107	0.0121	CbGpPWpGaD
Anagrelide—Decreased appetite—Epirubicin—liver cancer	0.00106	0.00116	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—liver cancer	0.00105	0.00115	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—liver cancer	0.00105	0.00115	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—liver cancer	0.00105	0.00115	CcSEcCtD
Anagrelide—Constipation—Epirubicin—liver cancer	0.00104	0.00114	CcSEcCtD
Anagrelide—Pain—Epirubicin—liver cancer	0.00104	0.00114	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00103	0.00112	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—liver cancer	0.00102	0.00112	CcSEcCtD
Anagrelide—CYP1A2—Estrogen metabolism—CYP1A1—liver cancer	0.00101	0.0115	CbGpPWpGaD
Anagrelide—Paraesthesia—Doxorubicin—liver cancer	0.00101	0.00111	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—liver cancer	0.001	0.0011	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—liver cancer	0.001	0.0011	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—liver cancer	0.001	0.0011	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—liver cancer	0.000994	0.00109	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—liver cancer	0.000991	0.00109	CcSEcCtD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000989	0.0112	CbGpPWpGaD
Anagrelide—Decreased appetite—Doxorubicin—liver cancer	0.000978	0.00107	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000971	0.00107	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—liver cancer	0.00097	0.00106	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—liver cancer	0.000966	0.00106	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—liver cancer	0.000962	0.00106	CcSEcCtD
Anagrelide—Pain—Doxorubicin—liver cancer	0.000962	0.00106	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—liver cancer	0.000961	0.00105	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—liver cancer	0.000961	0.00105	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—AHR—liver cancer	0.000935	0.0106	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—liver cancer	0.000935	0.0106	CbGpPWpGaD
Anagrelide—CYP1A2—Xenobiotics—CYP1A1—liver cancer	0.000932	0.0105	CbGpPWpGaD
Anagrelide—Feeling abnormal—Doxorubicin—liver cancer	0.000927	0.00102	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—ANXA2—liver cancer	0.000921	0.0104	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Doxorubicin—liver cancer	0.00092	0.00101	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—liver cancer	0.000912	0.0103	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—liver cancer	0.000912	0.0103	CbGpPWpGaD
Anagrelide—CYP1A2—Tamoxifen metabolism—CYP1A1—liver cancer	0.000897	0.0101	CbGpPWpGaD
Anagrelide—Urticaria—Doxorubicin—liver cancer	0.000894	0.000981	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—liver cancer	0.00089	0.000976	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—liver cancer	0.00089	0.000976	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—liver cancer	0.000873	0.000957	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—liver cancer	0.00086	0.000944	CcSEcCtD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000849	0.0096	CbGpPWpGaD
Anagrelide—Diarrhoea—Epirubicin—liver cancer	0.000832	0.000913	CcSEcCtD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—liver cancer	0.000818	0.00924	CbGpPWpGaD
Anagrelide—Asthenia—Doxorubicin—liver cancer	0.000807	0.000886	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—liver cancer	0.000804	0.000882	CcSEcCtD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000802	0.00907	CbGpPWpGaD
Anagrelide—Pruritus—Doxorubicin—liver cancer	0.000796	0.000873	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—liver cancer	0.000773	0.000848	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—liver cancer	0.00077	0.000845	CcSEcCtD
Anagrelide—Rash—Epirubicin—liver cancer	0.000767	0.000841	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—liver cancer	0.000766	0.00084	CcSEcCtD
Anagrelide—CYP1A2—Arachidonic acid metabolism—HPGDS—liver cancer	0.000765	0.00865	CbGpPWpGaD
Anagrelide—Headache—Epirubicin—liver cancer	0.000762	0.000836	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—liver cancer	0.000744	0.000816	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—UGDH—liver cancer	0.000729	0.00824	CbGpPWpGaD
Anagrelide—Nausea—Epirubicin—liver cancer	0.000722	0.000792	CcSEcCtD
Anagrelide—CYP1A2—Phase II conjugation—GSTA3—liver cancer	0.000716	0.00809	CbGpPWpGaD
Anagrelide—Vomiting—Doxorubicin—liver cancer	0.000715	0.000785	CcSEcCtD
Anagrelide—Rash—Doxorubicin—liver cancer	0.00071	0.000778	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—liver cancer	0.000709	0.000778	CcSEcCtD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—JUN—liver cancer	0.000706	0.00798	CbGpPWpGaD
Anagrelide—Headache—Doxorubicin—liver cancer	0.000705	0.000773	CcSEcCtD
Anagrelide—CYP1A2—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000693	0.00783	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.000691	0.00781	CbGpPWpGaD
Anagrelide—Nausea—Doxorubicin—liver cancer	0.000668	0.000733	CcSEcCtD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP2E1—liver cancer	0.000667	0.00753	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTA4—liver cancer	0.000655	0.0074	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTA2—liver cancer	0.000638	0.00721	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.000616	0.00696	CbGpPWpGaD
Anagrelide—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.00061	0.0069	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINA1—liver cancer	0.00061	0.0069	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.000609	0.00688	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CHN2—liver cancer	0.000594	0.00672	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.000572	0.00647	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000558	0.00631	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IFT88—liver cancer	0.000544	0.00615	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000539	0.00609	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000532	0.00601	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000487	0.0055	CbGpPWpGaD
Anagrelide—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000479	0.00541	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000479	0.00541	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000479	0.00541	CbGpPWpGaD
Anagrelide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000461	0.00521	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—TRIO—liver cancer	0.00046	0.0052	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IFNA1—liver cancer	0.000454	0.00514	CbGpPWpGaD
Anagrelide—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000448	0.00506	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CCR4—liver cancer	0.000441	0.00499	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000437	0.00494	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000426	0.00482	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000419	0.00473	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—TRIO—liver cancer	0.000418	0.00472	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000413	0.00467	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PRKCE—liver cancer	0.000402	0.00454	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CCR4—liver cancer	0.000401	0.00453	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000397	0.00449	CbGpPWpGaD
Anagrelide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000387	0.00438	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000383	0.00433	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ABL1—liver cancer	0.000383	0.00432	CbGpPWpGaD
Anagrelide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000382	0.00432	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IGF2—liver cancer	0.000381	0.00431	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000378	0.00427	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000373	0.00422	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000364	0.00412	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.00036	0.00407	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HGF—liver cancer	0.00036	0.00407	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000356	0.00403	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—CSF2—liver cancer	0.000356	0.00402	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000351	0.00397	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SHC3—liver cancer	0.000333	0.00377	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000327	0.0037	CbGpPWpGaD
Anagrelide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000314	0.00355	CbGpPWpGaD
Anagrelide—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.000301	0.0034	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000299	0.00338	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000294	0.00333	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—MAPK14—liver cancer	0.000288	0.00326	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000285	0.00322	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—F2—liver cancer	0.000279	0.00315	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.00027	0.00305	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.00027	0.00305	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CG—liver cancer	0.000267	0.00302	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000264	0.00298	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000263	0.00298	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FST—liver cancer	0.000259	0.00293	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000257	0.0029	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PRKCE—liver cancer	0.000254	0.00287	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000249	0.00281	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TRIO—liver cancer	0.000247	0.00279	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCR4—liver cancer	0.000237	0.00268	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CD—liver cancer	0.000235	0.00265	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—SERPINE1—liver cancer	0.000232	0.00262	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000232	0.00262	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—ALB—liver cancer	0.000232	0.00262	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PRKCE—liver cancer	0.000231	0.00261	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000229	0.00259	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CSF2—liver cancer	0.000225	0.00254	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000224	0.00254	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000213	0.00241	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—RAF1—liver cancer	0.00021	0.00237	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000206	0.00233	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000206	0.00233	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CB—liver cancer	0.000205	0.00231	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CSF2—liver cancer	0.000204	0.00231	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000192	0.00217	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000192	0.00217	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000191	0.00216	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000191	0.00216	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000189	0.00213	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—IL2—liver cancer	0.000188	0.00212	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADAM17—liver cancer	0.000187	0.00211	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—F2—liver cancer	0.000176	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMA4—liver cancer	0.000176	0.00199	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PSMD10—liver cancer	0.000176	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000176	0.00199	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000173	0.00196	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00017	0.00192	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CG—liver cancer	0.000169	0.00191	CbGpPWpGaD
Anagrelide—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000167	0.00188	CbGpPWpGaD
Anagrelide—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000164	0.00186	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000164	0.00185	CbGpPWpGaD
Anagrelide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000162	0.00183	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—F2—liver cancer	0.00016	0.00181	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—VEGFA—liver cancer	0.00016	0.00181	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CG—liver cancer	0.000153	0.00173	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CD—liver cancer	0.000148	0.00168	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TGFB1—liver cancer	0.000147	0.00166	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCE—liver cancer	0.000136	0.00154	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—KRAS—liver cancer	0.000136	0.00153	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CD—liver cancer	0.000135	0.00152	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CB—liver cancer	0.000129	0.00146	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF2—liver cancer	0.000129	0.00146	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000125	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—PIK3CA—liver cancer	0.000125	0.00141	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UGDH—liver cancer	0.000125	0.00141	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—TP53—liver cancer	0.000121	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CSF2—liver cancer	0.000121	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—RAF1—liver cancer	0.00012	0.00136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—H2AFX—liver cancer	0.000119	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—IL2—liver cancer	0.000119	0.00134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CB—liver cancer	0.000117	0.00133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EPT1—liver cancer	0.000117	0.00133	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—HRAS—liver cancer	0.000115	0.0013	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TAT—liver cancer	0.000111	0.00126	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000109	0.00124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL2—liver cancer	0.000108	0.00122	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TERT—liver cancer	0.000107	0.00121	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—liver cancer	0.000102	0.00115	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—liver cancer	9.83e-05	0.00111	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK14—liver cancer	9.76e-05	0.0011	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ESR1—liver cancer	9.58e-05	0.00108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2—liver cancer	9.46e-05	0.00107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APC—liver cancer	9.05e-05	0.00102	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CG—liver cancer	9.05e-05	0.00102	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—BRAF—liver cancer	8.51e-05	0.000962	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	8.18e-05	0.000925	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CD—liver cancer	7.96e-05	0.0009	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3CA—liver cancer	7.88e-05	0.000891	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—liver cancer	7.87e-05	0.00089	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—KRAS—liver cancer	7.79e-05	0.000881	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLUL—liver cancer	7.55e-05	0.000854	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CPT1B—liver cancer	7.55e-05	0.000854	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NR1H4—liver cancer	7.28e-05	0.000824	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA3—liver cancer	7.16e-05	0.00081	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3CA—liver cancer	7.16e-05	0.000809	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RAF1—liver cancer	7.11e-05	0.000803	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—liver cancer	6.94e-05	0.000784	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CB—liver cancer	6.94e-05	0.000784	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—HRAS—liver cancer	6.62e-05	0.000749	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA4—liver cancer	6.55e-05	0.00074	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1B—liver cancer	6.51e-05	0.000736	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—liver cancer	6.44e-05	0.000728	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.4e-05	0.000724	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA2—liver cancer	6.38e-05	0.000722	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CASP3—liver cancer	6.38e-05	0.000721	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL2—liver cancer	6.37e-05	0.00072	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—liver cancer	6.34e-05	0.000717	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCND1—liver cancer	6.21e-05	0.000702	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—JUN—liver cancer	6.2e-05	0.000701	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTA1—liver cancer	6.16e-05	0.000696	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CTNNB1—liver cancer	6.15e-05	0.000695	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NAT2—liver cancer	6.09e-05	0.000688	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—liver cancer	6.03e-05	0.000682	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—liver cancer	6.01e-05	0.000679	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK8—liver cancer	5.86e-05	0.000663	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.86e-05	0.000662	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—liver cancer	5.85e-05	0.000661	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDOB—liver cancer	5.84e-05	0.00066	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CRABP1—liver cancer	5.57e-05	0.00063	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—liver cancer	5.41e-05	0.000612	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STAT3—liver cancer	5.36e-05	0.000606	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.01e-05	0.000567	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—liver cancer	4.98e-05	0.000563	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—liver cancer	4.97e-05	0.000562	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HPGDS—liver cancer	4.87e-05	0.00055	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.84e-05	0.000547	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KRAS—liver cancer	4.6e-05	0.00052	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.41e-05	0.000498	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.35e-05	0.000492	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMD10—liver cancer	4.34e-05	0.000491	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PSMA4—liver cancer	4.34e-05	0.000491	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3CA—liver cancer	4.23e-05	0.000478	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT2—liver cancer	4.22e-05	0.000477	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—liver cancer	4.09e-05	0.000462	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2E1—liver cancer	3.97e-05	0.000449	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HRAS—liver cancer	3.91e-05	0.000442	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.84e-05	0.000434	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—liver cancer	3.74e-05	0.000423	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYCS—liver cancer	3.71e-05	0.00042	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GGT1—liver cancer	3.64e-05	0.000412	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT1—liver cancer	3.64e-05	0.000412	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—liver cancer	3.45e-05	0.000391	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTP1—liver cancer	3.27e-05	0.00037	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—liver cancer	3.23e-05	0.000365	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—liver cancer	3.01e-05	0.00034	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—liver cancer	2.85e-05	0.000322	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—liver cancer	2.66e-05	0.0003	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARA—liver cancer	2.61e-05	0.000295	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.34e-05	0.000265	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CG—liver cancer	2.23e-05	0.000252	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—liver cancer	2.16e-05	0.000244	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CD—liver cancer	1.96e-05	0.000222	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—liver cancer	1.94e-05	0.000219	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CB—liver cancer	1.71e-05	0.000193	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3CA—liver cancer	1.04e-05	0.000118	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—liver cancer	8.52e-06	9.63e-05	CbGpPWpGaD
